Exploring the Utility of Liquid Biopsy (ctdna) As a Translational Endpoint in Clinical Trials for Endometrial Cancer (012)

Biomarker predictors of response are incorporated into most modern treatment trials for recurrent endometrial cancer. Invasive procedures for tissue acquisition are often required for baseline assessment of molecular markers, making on-treatment biopsies more challenging. In this study, we explored the incidence of genetic mutations in pre-treatment biopsies, their correlation with pre-treatment ctDNA, and the change in mutation allele frequency (MAF) with therapy among women on an ongoing phase II trial.